As­traZeneca CEO Pas­cal So­ri­ot called on Eu­rope to step up in­vest­ments and “pro­tect its health sov­er­eign­ty” as it ...

Pfizer, Novartis, Amgen, Eli Lilly and J&J lead pharma lobbying spend amid policy changes. Issues include 340B program, drug ...

Zealand Pharma hires Eli Lilly veteran Utpal Singh as CSO to advance peptide platform, following Roche obesity drug deal and ...

A Bay Area protein design startup wants to build more potent antibody-drug conjugates, and is starting with $20 million in ...

Summit Therapeutics and Akeso said their PD-1xVEGF bispecific antibody ivonescimab beat BeiGene’s PD-1 blocker Tevimbra in a ...

Repertoire Immune Medicines makes a major announcement in April. And this year is no different. The Flagship ...

A small Northwestern University spinout attempting to develop a twist on biologics has pulled together a $30 million Series A ...

Eli Lilly on Thursday filed lawsuits against four telehealth companies over their sale of compounded versions of the GLP-1 ...

Boehringer Ingelheim has inked a research collaboration with Tessellate Bio to develop precision medicines for cancers that ...

Bristol Myers Squibb’s attempt to turn Cobenfy into a megablockbuster neuroscience drug ran into a stumbling block Tuesday ...

British drugmaker AstraZeneca is rejoining the drug industry's major US lobbying group, PhRMA, roughly two years after ...

For the first time since the Trump administration's major staff cuts at the FDA this month, the agency publicly announced that the firings will lead to a long delay for what would otherwise be a ...